{"id":"oxybutynin-er","safety":{"commonSideEffects":[{"rate":"29-72%","effect":"Dry mouth"},{"rate":"7-15%","effect":"Constipation"},{"rate":"17%","effect":"Dizziness"},{"rate":"14%","effect":"Somnolence"},{"rate":"7-10%","effect":"Headache"},{"rate":"8-10%","effect":"Blurred vision"}]},"_chembl":{"chemblId":"CHEMBL1231","moleculeType":"Small molecule","molecularWeight":"357.49"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"By antagonizing M3 muscarinic receptors on detrusor muscle, oxybutynin decreases the frequency and amplitude of bladder contractions. This anticholinergic action increases functional bladder capacity and reduces urinary urgency and incontinence episodes. The extended-release formulation provides sustained drug delivery over 24 hours, improving tolerability compared to immediate-release formulations.","oneSentence":"Oxybutynin is an anticholinergic agent that blocks muscarinic acetylcholine receptors in the bladder smooth muscle, reducing involuntary contractions and increasing bladder capacity.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:59:14.094Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Overactive bladder with symptoms of urge incontinence, urgency, and frequency"},{"name":"Neurogenic detrusor overactivity in patients with spinal cord injury or other neurological conditions"}]},"trialDetails":[{"nctId":"NCT06966778","phase":"NA","title":"Oxybutynin ER to Promote Early Continence Recovery After Robotic Prostatectomy: A Randomized Controlled Trial","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-09-15","conditions":"Localized Prostate Cancer, Postoperative Urinary Incontinence","enrollment":135},{"nctId":"NCT07114640","phase":"PHASE3","title":"The Effect of Nighttime Mirabegron, Solifenacin, Tolterodine, or Oxybutynin on Nocturia, Sexual Function, Autonomic Function, and Lower Urinary Tract Blood Flow Perfusion in Women With Overactive Bladder Syndrome: Randomized Controlled Trial","status":"NOT_YET_RECRUITING","sponsor":"Far Eastern Memorial Hospital","startDate":"2025-08-07","conditions":"Urinary Bladder, Overactive","enrollment":220},{"nctId":"NCT00649129","phase":"PHASE1","title":"Fasting Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":"Healthy","enrollment":36},{"nctId":"NCT00649259","phase":"PHASE1","title":"Food Study of Oxybutynin Chloride ER Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-10","conditions":"Healthy","enrollment":39},{"nctId":"NCT00649727","phase":"PHASE1","title":"Fed Study of Oxybutynin Chloride Extended-release Tablets 10 mg and Ditropan XL® Tablets 10 mg","status":"COMPLETED","sponsor":"Mylan Pharmaceuticals Inc","startDate":"2002-07","conditions":"Healthy","enrollment":24},{"nctId":"NCT05637671","phase":"PHASE3","title":"Efficacy and Safety of Oxybutynin Versus Paroxetine in Aromatase Inhibitor-induced Vasomotor Symptoms","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2022-02-10","conditions":"Vasomotor Symptoms","enrollment":146},{"nctId":"NCT00411437","phase":"PHASE4","title":"Effects Of Detrol LA On Memory And Cognition In Elderly Population","status":"COMPLETED","sponsor":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","startDate":"2006-12","conditions":"Memory, Cognition","enrollment":220},{"nctId":"NCT01824420","phase":"PHASE4","title":"Flexibly adding-on Second Antimuscarinic Agent to the First Antimuscarinics for Refractory Overactive Bladder Syndrome","status":"COMPLETED","sponsor":"Buddhist Tzu Chi General Hospital","startDate":"2013-03","conditions":"Overactive Bladder","enrollment":129},{"nctId":"NCT01050114","phase":"PHASE3","title":"OnabotulinumtoxinA (onaBoNT-A) Versus Oral Oxybutynin ER","status":"UNKNOWN","sponsor":"Christopher Patrick Smith","startDate":"2013-08","conditions":"Overactive Bladder","enrollment":36}],"_emaApprovals":[],"_faersSignals":[{"count":20,"reaction":"DRUG INEFFECTIVE"},{"count":18,"reaction":"FALL"},{"count":17,"reaction":"FATIGUE"},{"count":14,"reaction":"DIARRHOEA"},{"count":12,"reaction":"DIZZINESS"},{"count":10,"reaction":"PRURITUS"},{"count":9,"reaction":"HEADACHE"},{"count":8,"reaction":"DEATH"},{"count":8,"reaction":"DEPRESSION"},{"count":8,"reaction":"DRY MOUTH"}],"_approvalHistory":[],"publicationCount":24,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Ditropan XL","Urotrol","Oxytrol"],"phase":"marketed","status":"active","brandName":"Oxybutynin ER","genericName":"Oxybutynin ER","companyName":"Pfizer's Upjohn has merged with Mylan to form Viatris Inc.","companyId":"pfizer-s-upjohn-has-merged-with-mylan-to-form-viatris-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Oxybutynin ER is a small molecule that acts as a muscarinic acetylcholine receptor M3 antagonist. It is used to treat overactive bladder, a condition studied in various clinical trials.","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2003-02-26T00:00:00.000Z","mah":"ALLERGAN","brand_name_local":"OXYTROL","application_number":"NDA021351"}],"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}